Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 31-40 of 53 for

Edit search filters
  1. Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery

    Rochester, MN

  2. Ipilimumab Or High-Dose Interferon Alfa-2b In Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed By Surgery

    Jacksonville, FL

  3. Pembrolizumab And Ibrutinib In Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery

    Rochester, MN

  4. Comparison Of In-Home Versus In-Clinic Administration Of Subcutaneous Nivolumab Through Cancer CARE (Connected Access And Remote Expertise) Beyond Walls (CCBW) Program

    Jacksonville, FL

  5. MelmarT Melanoma Margins Trial Investigating 1cm V 2cm Wide Excision Margins For Primary Cutaneous Melanoma (MelMarT)

    Scottsdale/Phoenix, AZ, Jacksonville, FL

  6. Individualized Temozolomide in Treating Patients with Stage IV Melanoma that Cannot be Removed by Surgery

    Rochester, MN

  7. Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab Therapy

    Rochester, MN

  8. A Study To Evaluate UV1 Vaccination Plus Nivolumab And Ipilimumab In Treatment Of Melanoma

    Scottsdale/Phoenix, AZ

  9. Expanded Access Program With Nivolumab (BMS-936558) In Combination With Ipilimumab (Yervoy®) In Anti-CTLA-4 Treatment-Naïve Subjects With Unresectable Or Metastatic Melanoma (CheckMate 218)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  10. Ipilimumab And Nivolumab As Adjuvant Treatment Of Mucosal Melanoma

    Rochester, MN

.

Mayo Clinic Footer